scholarly journals Role of inorganic nanoparticle degradation in cancer therapy

2020 ◽  
Vol 2 (9) ◽  
pp. 3734-3763
Author(s):  
Christy Maksoudian ◽  
Neshat Saffarzadeh ◽  
Evelien Hesemans ◽  
Nora Dekoning ◽  
Kiana Buttiens ◽  
...  
Keyword(s):  
Cancer Therapy ◽  
Metal Oxide ◽  
Oxide Particle ◽  
Cancer Therapies ◽  
Selective Toxicity ◽  
Inorganic Nanoparticle ◽  
Metal Oxide Particle

Nanomaterials are widely exploited for developing novel cancer therapies. Here, we discuss the potential of cancer-selective toxicity of metal oxide particle degradation.

scholarly journals The Role of Herbal Bioactive Components in Mitochondria Function and Cancer Therapy

2019 ◽  
Vol 2019 ◽  
pp. 1-12 ◽  
Author(s):  
Fangfang Tao ◽  
Yanrong Zhang ◽  
Zhiqian Zhang
Keyword(s):  
Cancer Therapy ◽  
Cancer Cell ◽  
Apoptotic Cell ◽  
Redox Status ◽  
Cancer Therapies ◽  
Bioactive Components ◽  
Atp Production

Mitochondria are highly dynamic double-membrane organelles which play a well-recognized role in ATP production, calcium homeostasis, oxidation-reduction (redox) status, apoptotic cell death, and inflammation. Dysfunction of mitochondria has long been observed in a number of human diseases, including cancer. Targeting mitochondria metabolism in tumors as a cancer therapeutic strategy has attracted much attention for researchers in recent years due to the essential role of mitochondria in cancer cell growth, apoptosis, and progression. On the other hand, a series of studies have indicated that traditional medicinal herbs, including traditional Chinese medicines (TCM), exert their potential anticancer effects as an effective adjunct treatment for alleviating the systemic side effects of conventional cancer therapies, for reducing the risk of recurrence and cancer mortality and for improving the quality of patients’ life. An amazing feature of these structurally diverse bioactive components is that majority of them target mitochondria to provoke cancer cell-specific death program. The aim of this review is to summarize the in vitro and in vivo studies about the role of these herbs, especially their bioactive compounds in the modulation of the disturbed mitochondrial function for cancer therapy.

Metal oxide particle temperatures in flames

1970 ◽  
Vol 15 (2) ◽  
pp. 203-205 ◽  
Author(s):  
E.M. Bulewicz ◽  
P.J. Padley
Keyword(s):  
Metal Oxide ◽  
Oxide Particle ◽  
Metal Oxide Particle

scholarly journals Metal Oxide Particle Emissions from Diesel and Petrol Engines

2012 ◽  
Author(s):  
Andreas Mayer ◽  
Jan Czerwinski ◽  
Markus Kasper ◽  
Andrea Ulrich ◽  
John J. Mooney
Keyword(s):  
Metal Oxide ◽  
Oxide Particle ◽  
Particle Emissions ◽  
Metal Oxide Particle

scholarly journals MicroRNA-Based Combinatorial Cancer Therapy: Effects of MicroRNAs on the Efficacy of Anti-Cancer Therapies

Cells ◽  
2019 ◽  
Vol 9 (1) ◽  
pp. 29 ◽  
Author(s):  
Hyun Ah Seo ◽  
Sokviseth Moeng ◽  
Seokmin Sim ◽  
Hyo Jeong Kuh ◽  
Soo Young Choi ◽  
...  
Keyword(s):  
Cancer Therapy ◽  
Combination Therapy ◽  
Cancer Cells ◽  
Extracellular Vesicles ◽  
Therapeutic Resistance ◽  
Cancer Therapies ◽  
Anti Cancer ◽  
Different Types ◽  
Therapeutic Responses

The susceptibility of cancer cells to different types of treatments can be restricted by intrinsic and acquired therapeutic resistance, leading to the failure of cancer regression and remission. To overcome this problem, a combination therapy has been proposed as a fundamental strategy to improve therapeutic responses; however, resistance is still unavoidable. MicroRNA (miRNAs) are associated with cancer therapeutic resistance. The modulation of dysregulated miRNA levels through miRNA-based therapy comprising a replacement or inhibition approach has been proposed to sensitize cancer cells to other anti-cancer therapies. The combination of miRNA-based therapy with other anti-cancer therapies (miRNA-based combinatorial cancer therapy) is attractive, due to the ability of miRNAs to target multiple genes associated with the signaling pathways controlling therapeutic resistance. In this article, we present an overview of recent findings on the role of therapeutic resistance-related miRNAs in different types of cancer. We review the feasibility of utilizing dysregulated miRNAs in cancer cells and extracellular vesicles as potential candidates for miRNA-based combinatorial cancer therapy. We also discuss innate properties of miRNAs that need to be considered for more effective combinatorial cancer therapy.

Electrostatically Stabilized Metal Oxide Particle Dispersions in Carbon Dioxide

2005 ◽  
Vol 109 (43) ◽  
pp. 20155-20165 ◽  
Author(s):  
P. Griffin Smith ◽  
Won Ryoo ◽  
Keith P. Johnston
Keyword(s):  
Carbon Dioxide ◽  
Metal Oxide ◽  
Oxide Particle ◽  
Metal Oxide Particle

scholarly journals Role of rat sarcoma virus mutations in cancer and potential target for cancer therapy

2020 ◽  
pp. FSO455
Author(s):  
Sanjana S Murdande
Keyword(s):  
Cancer Therapy ◽  
Ras Signaling ◽  
Cancer Therapies ◽  
Ras Mutations ◽  
Ras Effectors ◽  
Sarcoma Virus ◽  
Direct Targeting ◽  
Robust Adaptive ◽  
Preclinical And Clinical Studies

The prevalence of oncogenic rat sarcoma virus (RAS) mutations has made RAS a popular target for cancer therapies. Significant discoveries have been reported regarding cancer molecular biology following the study of RAS mutations. These discoveries are integral in shaping the era of targeted cancer therapy, with direct targeting of RAS or downstream RAS effectors, such as Grb2 and MAPK a possibility. Novel agents such as farnesyltransferase directly bind and sequester RAS. While these new agents and approaches have shown promise in preclinical and clinical studies, the complexity of RAS signaling and the potential for robust adaptive feedback continue to present substantial challenges. Therefore, the development of targeted therapies will require a detailed understanding of the properties and dependencies of specific cancers to a RAS mutation. This review provides an overview of RAS mutations and their relationship with cancer and discusses their potential as therapeutic targets.

scholarly journals The Role of Biomarkers in Decreasing Risk of Cardiac Toxicity after Cancer Therapy

2016 ◽  
Vol 8s2 ◽  
pp. BIC.S31798 ◽  
Author(s):  
Christine Henri ◽  
Therese Heinonen ◽  
Jean-Claude Tardif
Keyword(s):  
Cancer Therapy ◽  
Natriuretic Peptides ◽  
Cardiac Toxicity ◽  
Myocardial Damage ◽  
Wall Stress ◽  
Left Ventricular ◽  
Cancer Therapies ◽  
Lv Dysfunction ◽  
After Cancer

With the improvement of cancer therapy, survival related to malignancy has improved, but the prevalence of long-term cardiotoxicity has also increased. Cancer therapies with known cardiac toxicity include anthracyclines, biologic agents (trastuzumab), and multikinase inhibitors (sunitinib). The most frequent presentation of cardiac toxicity is dilated cardiomyopathy associated with poorest prognosis. Monitoring of cardiac toxicity is commonly performed by assessment of left ventricular (LV) ejection fraction, which requires a significant amount of myocardial damage to allow detection of cardiac toxicity. Accordingly, this creates the impetus to search for more sensitive and reproducible biomarkers of cardiac toxicity after cancer therapy. Different biomarkers have been proposed to that end, the most studied ones included troponin release resulting from cardiomyocyte damage and natriuretic peptides reflecting elevation in LV filling pressure and wall stress. Increase in the levels of troponin and natriuretic peptides have been correlated with cumulative dose of anthracycline and the degree of LV dysfunction. Troponin is recognized as a highly efficient predictor of early and chronic cardiac toxicity, but there remains some debate regarding the clinical usefulness of the measurement of natriuretic peptides because of divergent results. Preliminary data are available for other biomarkers targeting inflammation, endothelial dysfunction, myocardial ischemia, and neuregulin-1. The purpose of this article is to review the available data to determine the role of biomarkers in decreasing the risk of cardiac toxicity after cancer therapy.

scholarly journals Preparation of Monodispersed Metal Oxide Particle from Normal Chain Metal Soaps. ZrO2 Particles from Zirconium Soaps.

1991 ◽  
pp. 1155-1160 ◽  
Author(s):  
Tokuko SUGIMURA ◽  
Yoshiharu FUJISAWA ◽  
Yoichi SHINDO ◽  
Ayao KITAHARA ◽  
Yuzo MASUDA
Keyword(s):  
Metal Oxide ◽  
Oxide Particle ◽  
Metal Oxide Particle ◽  
Metal Soaps
Sign in / Sign up

Export Citation Format

Share Document